173 related articles for article (PubMed ID: 30369578)
1. Nanoparticle-Mediated Targeting of Pitavastatin to Small Pulmonary Arteries and Leukocytes by Intravenous Administration Attenuates the Progression of Monocrotaline-Induced Established Pulmonary Arterial Hypertension in Rats.
Ichimura K; Matoba T; Koga JI; Nakano K; Funamoto D; Tsutsui H; Egashira K
Int Heart J; 2018 Nov; 59(6):1432-1444. PubMed ID: 30369578
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension.
Chen L; Nakano K; Kimura S; Matoba T; Iwata E; Miyagawa M; Tsujimoto H; Nagaoka K; Kishimoto J; Sunagawa K; Egashira K
Hypertension; 2011 Feb; 57(2):343-50. PubMed ID: 21220711
[TBL] [Abstract][Full Text] [Related]
3. Preventive treatment with atorvastatin ameliorates endothelial dysfunction of small pulmonary arteries in monocrotaline-induced pulmonary hypertensive rats.
Lin Z; Jiang Z; Huang X; Cai X; Wang H; Xie L
Clin Exp Hypertens; 2017; 39(6):495-501. PubMed ID: 28628347
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension.
Kimura S; Egashira K; Chen L; Nakano K; Iwata E; Miyagawa M; Tsujimoto H; Hara K; Morishita R; Sueishi K; Tominaga R; Sunagawa K
Hypertension; 2009 May; 53(5):877-83. PubMed ID: 19307469
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, and Pharmacokinetics of NK-104-NP.
Nakano K; Matoba T; Koga JI; Kashihara Y; Fukae M; Ieiri I; Shiramoto M; Irie S; Kishimoto J; Todaka K; Egashira K
Int Heart J; 2018 Sep; 59(5):1015-1025. PubMed ID: 30158384
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of beraprost sodium in nanoparticles: analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension.
Ishihara T; Hayashi E; Yamamoto S; Kobayashi C; Tamura Y; Sawazaki R; Tamura F; Tahara K; Kasahara T; Ishihara T; Takenaga M; Fukuda K; Mizushima T
J Control Release; 2015 Jan; 197():97-104. PubMed ID: 25449809
[TBL] [Abstract][Full Text] [Related]
7. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study.
McMurtry MS; Bonnet S; Michelakis ED; Bonnet S; Haromy A; Archer SL
Am J Physiol Lung Cell Mol Physiol; 2007 Oct; 293(4):L933-40. PubMed ID: 17675370
[TBL] [Abstract][Full Text] [Related]
8. A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model.
Nagaoka K; Matoba T; Mao Y; Nakano Y; Ikeda G; Egusa S; Tokutome M; Nagahama R; Nakano K; Sunagawa K; Egashira K
PLoS One; 2015; 10(7):e0132451. PubMed ID: 26167913
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Left Ventricular Remodeling After Acute Myocardial Infarction by Inhibiting Monocyte-Mediated Inflammation.
Mao Y; Koga JI; Tokutome M; Matoba T; Ikeda G; Nakano K; Egashira K
Int Heart J; 2017 Aug; 58(4):615-623. PubMed ID: 28701679
[TBL] [Abstract][Full Text] [Related]
11. 5-Aminosalicylic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats by Increasing the Expression of Nur77.
Sun LY; Cai ZY; Pu J; Li J; Shen JY; Yang CD; He B
Inflammation; 2017 Jun; 40(3):806-817. PubMed ID: 28213866
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension.
Segura-Ibarra V; Amione-Guerra J; Cruz-Solbes AS; Cara FE; Iruegas-Nunez DA; Wu S; Youker KA; Bhimaraj A; Torre-Amione G; Ferrari M; Karmouty-Quintana H; Guha A; Blanco E
Int J Pharm; 2017 May; 524(1-2):257-267. PubMed ID: 28359821
[TBL] [Abstract][Full Text] [Related]
13. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
15. Preventive and remedial application of etanercept attenuate monocrotaline-induced pulmonary arterial hypertension.
Zhang LL; Lu J; Li MT; Wang Q; Zeng XF
Int J Rheum Dis; 2016 Feb; 19(2):192-8. PubMed ID: 24612527
[TBL] [Abstract][Full Text] [Related]
16. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
17. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
[TBL] [Abstract][Full Text] [Related]
19. Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
Gao H; Cheng Y; Zong L; Huang L; Qiao C; Li W; Gong B; Hu J; Liu H; Wang X; Zhao C
Clin Exp Hypertens; 2017; 39(1):34-41. PubMed ID: 28055284
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
Eur J Pharmacol; 2018 May; 827():159-166. PubMed ID: 29453947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
